Compare BWB & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWB | EVO |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.1M | 568.6M |
| IPO Year | 2018 | 2007 |
| Metric | BWB | EVO |
|---|---|---|
| Price | $20.71 | $1.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $24.00 | $4.24 |
| AVG Volume (30 Days) | 71.7K | ★ 81.9K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.66 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.45 | N/A |
| Revenue Next Year | $11.22 | $20.47 |
| P/E Ratio | $20.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.06 | $1.33 |
| 52 Week High | $22.62 | $4.27 |
| Indicator | BWB | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 48.86 |
| Support Level | $19.58 | $1.50 |
| Resistance Level | $20.99 | $1.97 |
| Average True Range (ATR) | 0.43 | 0.06 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 52.73 | 56.25 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.